Nonanimal alternatives for skin sensitization: a step forward?
Basketter
David A
DA
St John's Institute of Dermatology, St Thomas Hospital, London SE1 7EH, UK. david.basketter@ukonline.co.uk
D000485:Allergens / Q000633:toxicity*; D023401:Animal Use Alternatives; D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D045744:Cell Line, Tumor; D003877:Dermatitis, Contact / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D004790:Enzyme Induction; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D017930:Genes, Reporter; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D000072019:Kelch-Like ECH-Associated Protein 1; D008156:Luciferases / Q000096:biosynthesis; D008198:Lymph Nodes / Q000187:drug effects; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000096:biosynthesis* / Q000235:genetics; D011401:Promoter Regions, Genetic / Q000187:drug effects*; D015203:Reproducibility of Results; D018570:Risk Assessment; D012882:Skin Tests; D014157:Transcription Factors / Q000378:metabolism; D014162:Transfection
D000485:Allergens; D000975:Antioxidants; D047908:Intracellular Signaling Peptides and Proteins; C431364:KEAP1 protein, human; D000072019:Kelch-Like ECH-Associated Protein 1; D014157:Transcription Factors; C101003:ELF2 protein, human; D008156:Luciferases; D016660:NAD(P)H Dehydrogenase (Quinone)